Text Size:AAA

ラット VCAM1/VCAM-1/CD106  遺伝子

All VCAM-1 Reagents


Browse VCAM1/VCAM-1/CD106 Products by

VCAM1/VCAM-1/CD106 Related Area

VCAM1/VCAM-1/CD106 関連経路

    VCAM1/VCAM-1/CD106 関連製品

    VCAM1/VCAM-1/CD106 関連製品

    Featured Reagent Products

    VCAM1/VCAM-1/CD106 サマリー & タンパク質情報

    VCAM1/VCAM-1/CD106 背景

    遺伝子の概要: This gene is a member of the Ig superfamily and encodes a cell surface sialoglycoprotein expressed by cytokine-activated endothelium. This type I membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of artherosclerosis and rheumatoid arthritis. Three alternatively spliced transcripts encoding different isoforms have been described for this gene.
    General information above from NCBI
    サブユニット構造: Binds to ECMV-D capsid proteins and acts as a receptor for this virus. {ECO:0000250}.
    ドメイン: Either the first or the fourth Ig-like C2-type domain is required for VLA4-dependent cell adhesion.
    細胞内位置: Membrane; Single-pass type I membrane protein.
    組織特異性: Expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue.
    誘導: By cytokines (e.g. IL-1, TNF-alpha).
    翻訳後: Sialoglycoprotein.
    シーケンスの類似性: Contains 7 Ig-like C2-type (immunoglobulin-like) domains. {ECO:0000305}.
    General information above from UniProt

    Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    VCAM1/VCAM-1/CD106 代替名

    CD106,INCAM-100, [homo-sapiens]
    CD106,DKFZp779G2333,INCAM-100,MGC99561,VCAM1,VCAM-1, [human]
    CD106,VCAM1,VCAM-1, [mouse]
    CD106,Vcam-1, [mus-musculus]

    VCAM1/VCAM-1/CD106 関連研究

  • Cook-Mills JM. (2002) VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 39(9): 499-508.
  • Preiss DJ, et al. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 61(4): 697-701.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"